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Animal tumour models using orthotopic tumours for the evaluation of cancer therapies are of greater clinical relevance than
subcutaneous models, but they also pose greater difficulties for measuring tumour size and quantifying response to treatment. In this
study, we used noninvasive bioluminescence imaging to monitor the intraperitoneal growth of luciferase-transfected CC531
colorectal cells in adult WAG/RIJ rats. The bioluminescence signal correlated well with post-mortem assessment of tumour load by
visual inspection of the peritoneal cavity at specific follow-up times. Using bioluminescence imaging, we were able to monitor
peritoneal tumour growth sequentially in time and to calculate a tumour growth rate for each animal; this is not possible with invasive
methods of evaluating tumour load. Bioluminescence imaging of rats treated with a single dose of cisplatin (4mgkg
 1, i.p.)
demonstrated a significant delay in peritoneal tumour growth relative to saline controls (mean 45.07s.d. 13.0 vs 28.2710.3 days;
P¼0.04). Similar protocols evaluated by visual scoring of tumour load at 40 days after inoculation supported these findings, although
no quantitative assessment of treatment-induced growth delay could be made by this method. This study shows that in vivo imaging of
luciferase-transfected tumour cells is a useful tool to investigate the dynamics of disseminated tumour growth and efficacy of
anticancer treatment in orthotopic models of peritoneal cancer in rats. It offers an attractive alternative to invasive methods, and
requires fewer animals for measuring tumour response to therapy.
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Locally disseminated peritoneal surface malignancy is a major
problem in the management of abdominal cancers. In all, 10% of
patients with primary colorectal cancer initially present with
peritoneal seeding and 25–35% of patients who underwent
seemingly curative surgery will later develop peritoneal metastases
(Swedish Rectal Cancer Trial, 1997). Once peritoneal spread has
occurred, survival is only 10–12 months, despite systemic
chemotherapy. There is therefore an urgent need for improve-
ments in treatment. An aggressive treatment modality currently
under investigation for the treatment of colorectal cancer
combines cytoreductive surgery with Hyperthermic Intraoperative
Peritoneal Chemotherapy (HIPEC), followed by systemic che-
motherapy. The aim with HIPEC is to achieve high local drug
concentrations in direct contact with small peritoneal tumour
deposits, with mild hyperthermia used to increase drug penetra-
tion. This technique was pioneered by Spratt et al (1980) and has
since been evaluated in several clinical studies (Sugarbaker et al,
1996; Ceelen et al, 2000). A randomised phase III trial recently
showed a significant survival benefit for HIPEC compared with
systemic chemotherapy alone (Witkamp et al, 2001; Verwaal et al,
2003). However, it is not clear what effect each component of the
HIPEC treatment (surgery, local perfusion, hyperthermia) has on
the tumour response. Animal studies are required to identify the
relative importance of different components of such multimodality
therapies and to compare the effects of chemotherapy delivered by
different routes.
Until now, the most commonly used method to determine
tumour load in the abdominal cavity of animals is to kill the
animals and score the size and number of tumours at various times
after treatment (Los et al, 1989; Rose et al, 1996). Using such an
approach, different animals have to be killed at sequential time
points to determine the average course of tumour development
and growth. This leads to the use of a large number of animals and
gives an estimate of the mean tumour size, in different groups of
animals, at different follow-up times. It is impossible to follow the
kinetics of tumour growth and response to treatment in individual
animals using such an invasive procedure. In addition, the precise
tumour burden at the time of treatment is unknown, leading to
uncertainty in the evaluation of treatment efficacy.
Recently, a new method of noninvasive bioluminescence
imaging has been developed for in vivo use (Contag et al, 1997).
Bioluminescence imaging is based on the expression of luciferase,
the light-emitting enzyme of the firefly Photinus pyralis (De Wet
et al, 1987). After the administration of the substrate luciferin, an
ATP- and O2-dependent photochemical reaction occurs, resulting
in the release of photons by living cells containing luciferase. This
photon emission can be detected by a cooled charge-coupled
device (CCD) camera, minutes after the administration of the
substrate. Bioluminescence imaging has been used successfully for
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smonitoring tumour growth in mice (Sweeney et al, 1999; Edinger
et al, 1999; Vooijs et al, 2002; Wetterwald et al, 2002). There are
also two reports of bioluminescence imaging in rats, to detect
localised glioma growth in the brain (Rehemtulla et al, 2000), or to
detect cardiac reporter gene expression in the heart (Wu et al,
2002). There are, to our knowledge, no previous reports using
bioluminescent imaging to detect multifocal orthotropic tumour
growth in the rat peritoneal cavity.
The aim of the present study was to determine whether
bioluminescence detection offers advantages (eg increased sensi-
tivity or reduced number of animals required to demonstrate an
effect) for quantitative assessment of anticancer therapies directed
against disseminated peritoneal colorectal cancer. We report on
the noninvasive, in vivo imaging of the intraperitoneal growth of
luciferase-transfected colorectal cancer cells in rats. This new
method of monitoring the kinetics of tumour growth was
compared with post-mortem scoring of tumour load after
intraperitoneal treatment with cisplatin.
MATERIAL AND METHODS
Cells
Rat colorectal CC531 cells (Zedeck and Sternberg, 1974) were
maintained in DMEM with 10% foetal calf serum (FCS) (Gibco,
Breda, the Netherlands), penicillin (100Uml
 1) and streptomycin
(100Uml
 1). These cells give rise to disseminated peritoneal
tumour nodules after i.p. injection in syngeneic WAG/RIJ rats (Los
et al, 1989).
Animals
Female WAG/RIJ rats, bred at the animal department of the
Netherlands Cancer Institute, weighing 180–200g (age 3–5
months), were used in this study. All protocols were approved
by the local Animal Experimentation Committee and carried out in
compliance with national guidelines for the care and use of
research animals.
Tumour response experiments
Rats were inoculated i.p. with CC531 cells (1 10
6) and treated at
10 days after tumour cell inoculation, by which time small (1–
2mm) peritoneal tumours were established at 1 or more peritoneal
sites. Treatment groups consisted of a single i.p. bolus injection of
cisplatin (Vianex S.A., New Erythrea, Greece; 4mgkg
 1 in 20ml
saline) or a 90min intraperitoneal perfusion at 40 or 371C with or
without cisplatin (200ml at 8mgml
 1). Previous studies in rats had
demonstrated that approximately 30–35% of the cisplatin
administered during such a 90min peritoneal perfusion was
absorbed systemically (Zeamari et al, 2003). The total absorbed
cisplatin dose in the perfused rats was therefore slightly lower than
in the bolus injection regimes (approximately 3mgkg
 1), but
higher perfusate concentrations were associated with renal toxicity
and were poorly tolerated. Animals were killed and the intraper-
itoneal tumour load was determined at 40 days after inoculation.
Tumour load was scored according to a point scale indicating large
(45mm: 3 points), moderate (1–5mm: 2 points), small (o1mm:
1 point) or no tumour (0 points) in seven abdominal regions
(pelvis, omentum, transverse colon, mesentery, left and right
subdiaphragmatic area, subhepatic area). These scores were added
to give the total peritoneal tumour load (maximum score 21
arbitrary units).
Intraperitoneal perfusion
Rats were anaesthetised by i.m. injection of a mixture of Hypnorm
(fentanyl: 0.15mgkg
 1; fluanosine: 5mgkg
 1) and Dormicum
(midazolan, 2.5mgkg
 1). Prior to perfusion, animals were injected
i.v. with 42mgkg
 1 gelofusin (B. Braun, Melsungen, Germany) to
increase the resistance of the veins to the pressure of the peritoneal
perfusion fluid, as described previously (Zeamari et al, 2003). A
median incision was made in the abdominal wall and the skin was
sutured to a retractor ring above the abdomen, to create a basin for
the perfusion fluid. Inflow and outflow catheters were introduced
through the abdominal wall and connected to a heat exchanger and
a regulated vacuum reservoir, as described previously (Zeamari
et al, 2003). The perfusion system was filled with 200ml isotonic
dialysis fluid (Dianeal
s PD1; Baxter, Unterscleissheim, Germany)
and perfusion continued for 90min after reaching the required
temperature (37 or 401C). Cisplatin was added to the system to
achieve the required drug concentration (8mgml
 1) at the start of
the timed perfusion. At the end of the 90min perfusion, the
perfusate was aspirated and the wound was closed.
Luciferase transfections
CC531 cells were cotransfected with the firefly luciferase gene
(pGL3) in combination with a vector for puromycin resistance
(pHA262pur) or for green fluorescent protein (GFP) and neomycin
resistance, using lipofectin reagent (Life Technologies, USA) or
electroporation, respectively. Molar ratios of 10:1 were used for
luciferase:selection plasmids.
At 24h before transfection with lipofectin, cells were seeded at a
density of 2 10
5 per six-well plate. A total of 1mg vector DNA was
then added to 100ml Optimem medium (Gibco, Breda, Nether-
lands) and incubated for 30min at room temperature before
mixing with 100ml lipofectin solution (2–20ml in 100ml Optimem)
and incubating for an additional 15min. Plated cells were washed
and 0.2ml of the DNA/lipofectin mixture and 1.8ml serum-free
DMEM were added prior to overnight incubation at 371C.
Transfection medium was then replaced by fresh DMEM, contain-
ing 10% FCS, antibiotics and puromycin (5mgml
 1). The resulting
colonies were harvested and cultured independently to select for
the highest luciferase activity.
Electroporation transfections were carried out using a Gene-
pulser equipped with an RF module (Bio-rad). A total of 4 million
cells were suspended in 950ml of HEPES-buffered mannitol buffer.
Luciferase and GFP plasmid (10mg) (EGFP-N3, Clontech) were
added to the cell suspension and incubated for 5min at room
temperature prior to electroporation at 350V. Cells were then
incubated at 371C for 48h before selection by incubation with
800mgml
 1 neomycin (Genetecin; Gibco, Breda, Netherlands).
Biochemical luciferase assay
Luciferase activity was measured using the Dual Luciferase Assay
kit (Promega, Madison, USA). Cell suspensions were made with
approximately 10
5 luciferase-transfected cells in 100ml lysis buffer.
Protein concentration was measured using pyrogallol total protein
reagent (Instruchemie, Hilversum BV, Netherlands) according to
the manufacturer’s instructions. Luciferin substrate (50ml) was
added to 5ml aliquots of cell lysates to determine the luciferase
enzyme activity, using a Top Count Luminescence Counter
(Perkin-Elmer Life Sciences, Boston, USA). Each lysate was
measured twice and luciferase activity, corrected for protein
content, was expressed as relative light units (RLUs).
In vivo bioluminescence imaging
All animals were imaged using a cooled CCD camera (Xenogen
IVIS, Xenogen, Alameda, USA), coupled to the LivingImage
acquisition and analysis software (Xenogen Corp.). To determine
the detection limits of CC531-luc cells in rats, an increasing
number of tumour cells was initially inoculated within the
abdominal wall, immediately followed by the injection of luciferin
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sand imaging of photon emission after 10min. On the basis of this
result, images were subsequently made at various time points after
i.p. inoculation of 2 10
6 CC531-luc cells to monitor the dynamics
of peritoneal tumour growth.
Before imaging, the abdomen of the rats was shaved to minimise
photon scattering and signal quenching. D-luciferin (Xenogen) was
dissolved at 15mgml
 1 in sterile PBS and stored at  201C.
Animals were anaesthetised with hypnorm (fentanyl: 0.15mgkg
 1;
fluanosine: 5mgkg
 1) and Dormicum (midazolam: 2.5mgkg
 1)
prior to injection with luciferin (150mgg
 1 body weight, i.p.).
Peritoneal light emission was measured over an integration time of
1min, and images were acquired using Ivis and LivingImage
software. Signal intensity was quantified as the total counts
measured over the region of interest.
One group of rats (n¼5) was followed sequentially at weekly
intervals from 1 to 5 weeks after inoculation and then killed for
visual inspection of peritoneal tumour load. Separate groups of
rats (n¼5 or 6 per time point) were imaged at 1, 2, 3 or 4 weeks
immediately prior to post-mortem evaluation by visual inspection.
Peritoneal luciferase activity was correlated with the distribution
and size of tumours determined using the scoring system
described.
Bioluminescence imaging of effect of i.p. cisplatin
treatment on tumour growth
Rats were inoculated with 2 10
6 CC531-luc cells i.p. prior to
sequential imaging at weekly intervals. These images showed that
the majority of animals had a detectable luciferase signal after 1
week. Animals with detectable signal were assumed to be tumour
bearing and were subsequently treated on days 8–10 with either
cisplatin (4mgkg
 1 in 20ml saline, i.p.), saline only (20ml, i.p.) or
no treatment (n¼5–7 per group). Luciferase activity was imaged
weekly (for a maximum of 11 weeks) to determine the effect of the
treatment on tumour growth. Animals were killed when the
peritoneal RLU count was 42000 10
3.The time taken for
peritoneal RLU signal to increase by 1000 counts above the
starting value (on days 8–10 after inoculation) was calculated for
each rat; this was termed ‘tumour regrowth time’.
RESULTS
Effect of cisplatin treatment on intraperitoneal tumour
growth
CC531 cells grew intraperitoneally in WAG/RIJ rats and induced
superficial tumours at several sites in the abdominal cavity,
including omentum, mesentery, pelvis and subhepatic and
subdiaphragmatic area. However, there was a large variation in
tumour load within each group of animals killed at different times
after inoculation (Figure 1). At 40 days after inoculation, the
tumour load ranged from 1 or 2 small nodules (a point score of 3)
to extensive multifocal disease throughout the peritoneal cavity
(score 21). Since this tumour scoring system is only semiquanti-
tative, and different rats were examined at each time point, it is not
possible to calculate tumour volume doubling times or growth
rates from these data.
Separate groups of rats were treated with cisplatin given either
as an i.p. bolus injection (4mgkg
 1 in 20ml saline) or intra-
abdominal perfusion at 37 or 401C( 8mgml
 1 in 200ml Dianeal),
10 days after inoculation with CC531 cells. The tumour load was
assessed post-mortem at 40 days after inoculation (Figure 2).
These results show a significant reduction in tumour load after
cisplatin given as an i.p. bolus injection (P¼0.03, relative to saline
controls). There was no reduction in tumour load after
normothermic or hyperthermic perfusion with cisplatin, relative
to perfuate-only controls (P40.5). The i.p. bolus cisplatin
treatment protocol was subsequently selected for evaluating the
usefulness of bioluminescence imaging to detect tumour response
to therapy.
Luciferase expression in CC531cells
The highest in vitro luciferase activity detected in CC351
transfected cells was 4.2 10
5 countsmg
 1 protein after lipofectin
transfection (CC531-luc1) and 2.9 10
3 countsmg
 1 after electo-
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Figure 1 Intraperitoneal tumour load in individual rats at 10 to 40 days
after inoculation of 1 10
6 CC531 cells. The tumour load (in arbitrary
units) was estimated by visual inspection at post-mortem, according to a
point scale combining number and size of nodules (see Materials and
methods).
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Figure 2 Mean tumour load (7s.d.) estimated for groups of treated
(n¼5–7) and untreated rats (n¼11) at 40 days after inoculation with
CC531 cells. Control rats received no surgical treatment or drugs;  CP
perf¼90min perfusion at 371C with 200ml Dianeal perfusate only; þCP
perf/37¼90min perfusion at 371C with cisplatin in 200ml Dianeal
(8mgml
 1); þCP perf/40¼90min perfusion at 401C with cisplatin in
200ml Dianeal (8mgml
 1); saline i.p.¼bolus injection of 20ml saline (i.p.);
þCP i.p.¼bolus injection of cisplatin (4mgkg
 1) in 20ml saline (i.p.).
Tumour load for cisplatin bolus injection was significantly lower than for i.p.
saline controls (*).
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sporation (CC531-luc2). There was no difference in the in vitro
growth of CC531 parental cells and CC531-luc1 or -luc2 cells,
indicating that the transfection procedure had no effect on the in
vitro growth ability (data not shown). These two cell lines were
used for further in vivo studies.
Both the transfected cell lines CC531-luc1 and CC531-luc2
produced tumours in immune suppressed nude mice when
injected subcutaneously or i.p. However, only the electroporation-
transfected CC531-luc2 cells grew in immune competent WAG/RIJ
rats. The detection limit for CC531-luc2 cells, imaged immediately
after injection in the rat abdominal wall, was 10
5 cells.
The first peritoneal tumour nodules were visible by manual
inspection about 1 week after i.p. inoculation of CC531-luc2 cells;
that is, earlier than after i.p. inoculation of rats with the parental
CC531 cells. This reflects the change in protocol to inject 2 10
6
transfected cells compared with 1 10
6 parental cells. However,
there was no significant difference in the in vivo growth rates of
CC531-luc2 cells compared with the parental cells; the mean
tumour loads increased from about 5 to 12 arbitrary units over a 4-
week period (Figure 3).
Bioluminescence imaging of tumours in animals
Intraperitoneal growth of CC531-luc2 tumour cells was sequentially
monitored in a group of five rats, using the total light emission
over the peritoneal cavity as an indication of tumour burden.
Peritoneal luciferase activity could be detected in rats from 1 to 2
weeks after inoculation of 2 10
6 CC531-luc2 cells. The peritoneal
tumour distribution, estimated by visual inspection at the time of
killing, correlated with the regions of bioluminescence activity
(Figures 4A and B). Relative light units increased with time after
inoculation (Figure 4C and D), and the time taken for peritoneal
luminescence scores to increase from 100 to 1000 10
3 counts
ranged from 2 to 45 weeks.
Separate groups of tumour-bearing rats were also imaged and
then killed to estimate tumour load at 1, 2, 3 and 4 weeks after
inoculation. There was a good overall correlation (r¼0.75)
between bioluminescence imaging and tumour load for individual
rats (Figure 5). However, there was one rat with obvious tumour
nodules visible at post-mortem that were not detected by
bioluminescence. This rat had tumours in the subhepatic region,
which were shielded by the liver and stomach; nodules in other
regions were o2mm.
Response to chemotherapy in vivo
In vivo imaging of luciferase activity of CC531-luc2 cells was
subsequently used to determine the effect of i.p. bolus injection
with cisplatin on intraperitoneal tumour growth in WAG/RIJ rats
(Figure 6). Four of the seven cisplatin-treated rats clearly had
slower progression of their peritoneal disease than untreated rats,
or rats given a bolus injection of saline. Tumour progression was
unchanged in two rats and one rat had variable RLU signals from
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Figure 3 Mean tumour load (7s.d.) estimated, by visual inspection at
post-mortem, for groups of rats at various times after inoculation with
1 10
6 CC531 cells (K), or 2 10
6 CC531-luc2-transfected cells (J).
Groups comprise four to five rats, or seven to 10 rats (CC531 cells at 35
and 40 days).
Figure 4 Correlation of external bioluminescence imaging of rats (A)
with location of tumour (B) at 21 days after inoculation of CC531- luc2
cells. The scale to the right of the image (A) describes the colour map for
the luminescence signal (RLU). C) shows increasing bioluminescence signals
in six rats imaged repeatedly from 1 to 5 weeks after tumour cell
inoculation. Group mean values (7s.d.) for these rats are shown in (D)
(n¼3 at 1 week, n¼6 at other times).
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Figure 5 Correlation between bioluminescence signal (measured
immediately before killing) and post-mortem evaluation of tumour load
(r¼0.75). Data are for individual, untreated rats at 1–5 weeks after
CC531-luc2 cell inoculation.
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sweek to week. The group mean tumour regrowth time (time
required for the bioluminescence signal to increase by 1000 RLU)
for cisplatin-treated rats was significantly longer than that for
saline-treated rats rats: 45.0713.1 (s.d.) vs 28.2710.3 days
(P¼0.038), or for untreated rats (19.076.8 days, P¼0003). There
was no significant difference between the untreated control group
and the group given i.p. saline (Figure 7).
DISCUSSION
Sensitive and noninvasive methods for measuring tumour load are
needed to evaluate and compare the efficacy of different cancer
treatments in vivo. Our study demonstrates, for the first time, that
in vivo bioluminescence imaging of luciferase-transfected cells can
be used for the effective assessment of disseminated peritoneal
tumour growth and response to treatment in rats, thereby
extending its use beyond imaging of focal superficial tumours.
Tumour nodules of 2–3mm could be detected in the peritoneal
cavity, providing thick, pigmented organs, like the liver, did not
shield them. This technique therefore offers an attractive
alternative to more commonly used invasive methods, in which
groups of animals are killed and tumour load estimated by visual
inspection or excision and weighing at different time points after
treatment (Los et al, 1989; Rose et al, 1996).
As part of our ongoing investigation to compare the efficacies of
various treatments against disseminated peritoneal cancer, we
initially used visual, post-mortem inspection of tumour load at
various times after inoculation with CC531 cells. This revealed
substantial differences between the rats. Such a variation in tumour
growth rate inevitably resulted in a wide range of tumour burdens in
animals treated at a prespecified time after inoculation. Despite this
variation, we were able to demonstrate a significant reduction in
tumour load after treatment with a bolus injection of cisplatin at
4mgkg
 1, close to the MTD, although no reduction in tumour
burden was seen for perfusion with cisplatin at MTD (8mgml
 1).
Previous studies demonstrated that peritoneal perfusion with
15mgml
 1 cisplatin (at 37 or 401C) was required to give the same
tumour concentration as an i.p. bolus injection of 4mgkg
 1
(Zeamari et al, 2003). These schedules also resulted in similar
plasma drug levels, which suggests that the drug concentration in
small peritoneal tumours was largely determined by systemic
exposure, rather than peritoneal drug concentrations. In the present
study, the concentration of cisplatin in the perfusate had to be
reduced, in order to avoid excessive renal toxicity. This must have
resulted in lower tumour drug concentrations than the i.p. bolus
injections (although these were not measured in the present study),
which is probably the reason for the lack of efficacy for the perfusion
schedules used. These observations, although not conclusive, do not
lend any support to the proposals for an improved therapeutic ratio
for hyperthermic, peritoneal, perfusion with low doses of cisplatin.
To overcome the disadvantages of invasive monitoring of
tumour growth, we subsequently used in vivo bioluminescence
imaging of luciferase-transfected CC531 cells. We started with
CC531-luc1 cells, transfected using lipofectin reagent. This gave
good luciferase activity and we were able to monitor the
intraperitoneal growth of these CC531-luc1 cells in nude BALB/c
mice by external, bioluminescence imaging. These CC531-luc1 cells
were, however, not able to form tumours after inoculation in
WAG/RIJ rats. The reason for this was probably immunogenicity
induced by the transfection process. Parental CC531 cells were
subsequently transfected using electroporation, which resulted in a
much lower level of luciferase gene expression (by a factor of
4100) compared to lipofectin transfection. These CC531-luc2 cells
did grow in the peritoneal cavity of the WAG/RIJ rats and no
significant differences between growth rates of parental and
transfected cells were seen. The high level of transfected gene
expression in CC531-luc1 cells could have been responsible for
their inability to form tumours in immunocompetent rats. It has
been previously reported that expression of high levels of a
transfected gene, for example, GFP, in mouse BM185 leukaemia
cells resulted in a drastic reduction in disease development in
immunocompetent mice, whereas in immunodeficient Nu/Nu mice
the disease developed rapidly (Stripecke et al, 1999).
Using in vivo imaging of luciferase-transfected cells, long-
itudinal data could be acquired, monitoring the intraperitoneal
distribution and growth of tumour cells with time after inocula-
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Figure 6 Bioluminescence signals in seven individual rats imaged at
weekly intervals after an i.p. bolus injection of cisplatin (A). The group mean
values (7s.d.) for these rats (J) are compared with saline controls (n¼7,
m) and untreated rats (n¼5, K)i n( B).
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Figure 7 Tumour regrowth times (mean7s.d.) for cisplatin-treated
(n¼7) and control rats (n¼5–7), calculated as the time taken for the RLU
signal to increase by 1000 counts above the value at treatment (440 RLU).
Cisplatin-treated rats had significantly longer regrowth times (*) than
untreated (P¼0.003) or saline-treated rats (P¼0.038). There was no
significant difference between untreated and saline controls.
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stion. This also allowed us to specify a minimum tumour burden at
the time of treatment and a maximum tumour burden prior to
killing the animals. Neither of these can be done when tumour load
is evaluated by invasive methods at specific, preplanned times.
Comparison of the tumour load evaluated by bioluminescence and
post-mortem visual inspection revealed good correlations
(r¼0.75) with regard to both the extent and distribution of
tumour, despite the multiple tumour foci at variable depth in the
peritoneal cavity. Small tumours within the liver mass could not be
easily detected by bioluminescence.
Bioluminescence imaging was used to monitor responses to a
bolus, i.p. injection of cisplatin. Early response (tumour regres-
sion) was followed by subsequent regrowth of tumours. This could
be detected well before the appearance of the common end points
of weight loss, palpable tumours or death. A significant effect of
cisplatin treatment on tumour growth, determined by in vivo
bioluminescence, has already been reported in mice (Sweeney et al,
1999). However, this is the first study that shows such an effect in
rats, using a bioluminescence technique.
Despite the advantages and convenience of bioluminescence
imaging for monitoring tumour growth, there are some disadvan-
tages. Firstly, light transmission is attenuated by tissue; therefore
the deeper the tumours lie within the body, the greater the signal
attenuation. This means that tumour load from deeper parts of the
body will be relatively under-represented in the integrated images.
It also means that small tumours that are shielded by bulky,
pigmented organs may well be missed. Light–coloured organs, like
prostate and mammary tissue or lungs, will tend to scatter rather
than absorb the light, so the bioluminescence signal from tumour
cells within such organs should be much less attenuated.
A second disadvantage of bioluminescence detection is that this
procedure involves transfection of the parental cell line. The
resulting clones do not always behave in exactly the same way as
the parental cells, as was demonstrated by the inability of CC531-
luc1-transformed cells to grow in immunocompetent rats. Ideally,
one would like to use clones expressing very high levels of the
reporter gene, since this will enhance detection sensitivity. However,
high expression levels of the transfected gene are also the most likely
to introduce unwanted phenotypic changes, for example, immuno-
genicity and altered growth rates. In reality, a compromise between
high luciferase expression and no, or minimal, changes in tumour
cell behaviour will probably need to be sought. In any case, each
transfected cell line should be checked for altered tumour growth
before use in evaluating treatment responses.
Alternative noninvasive techniques, such as PET, might overcome
some of the limitations of bioluminescence detection of orthotropic
tumour growth. However, this is a very expensive technique and it is
not widely available for preclinical animal studies. PET may also be
associated with its own problems, since the radioisotopes used tend
to accumulate in excretion organs (liver, kidneys, bladder), which
could interfere with the detection of small tumours in the peritoneal
cavity. A direct comparison of these techniques would be
interesting, but is outside the scope of the present study.
In summary, we showed that in vivo bioluminescence imaging of
tumour cells enables a rapid, noninvasive measurement of tumour
load before, during and after treatment of rats with disseminated
peritoneal disease. Using this technique, our understanding of in
vivo tumour development and response to current and novel
treatments can be increased.
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